Procept BioRobotics Reports Q3 Revenue Growth and Outlines 2026 Financial Guidance
Procept BioRobotics (PRCT) reported third-quarter revenue of $98.3 million, representing an 18% increase year-over-year. The company's procedural volume also saw significant growth, with over 13,400 U.S. procedures completed, a 22% rise compared to the previous year, driven largely by adoption of its HYDROS accounts. Looking ahead, management provided optimistic long-term guidance, projecting annual revenue between $390 million and $410 million for 2026. Additionally, the company is targeting positive adjusted EBITDA as early as the fourth quarter, signaling a strategic shift toward improved profitability alongside its current expansion.
Tickers: $PRCT
Topics: earnings report medical technology revenue growth robotic surgery
Read the full article at Seeking Alpha
Part of the story Sunrun Reports Q3 2026 Revenue Growth Amidst Lowered Cash Generation Guidance (25 articles)